Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer.

Journal of medicinal chemistry - 8 Jun 2023

Ma Lin, Li Yingying, Luo Ruixiang, Wang Yuhan, Cao Jiaqi, Fu Weitao, Qian Bolan, Zheng Lei, Tang Longguang, Lv Xinting, Zheng Lulu, Liang Guang, Chen Lingfeng

Abstract excerpt

Abnormal activation of fibroblast growth factor receptors (FGFRs) results in the development and progression of human cancers. FGFR2 is frequently amplified or mutated in cancers; therefore, it is an attractive target for tumor therapy. Despite the development of several pan-FGFR inhibitors, their long-term therapeutic efficacy is hindered by acquired mutations and low isoform selectivity. Herein, we report the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphorylation

Share to Protein Kinase Inhibitors

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Signal Transduction

Share to Stomach Neoplasms

Source

Identifiers

PMID: 37220310
DOI: 10.1021/acs.jmedchem.3c00150

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer.PMID 37220310Read ↗

A Selective FGFR1/2 PROTAC Degrader with Antitumor ActivitySemantic proximity Read ↗

Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor.Semantic proximity Read ↗

Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.Semantic proximity Read ↗

CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers.Semantic proximity Read ↗

Future applications of FGF/FGFR inhibitors in cancer.Semantic proximity Read ↗

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.Semantic proximity Read ↗

FGFR-TKI resistance in cancer: current status and perspectives.Semantic proximity Read ↗

Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.Semantic proximity Read ↗

FDA-approved kinase inhibitors in PROTAC design, development and synthesisSemantic proximity Read ↗

Acquired FGFR2 mutation leads resistance to pemigatinib in a patient with FGFR2-driven Borrmann type IV gastric cancer.Semantic proximity Read ↗

Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.Semantic proximity Read ↗

Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 ProteinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.